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ABSTRACT:  The trough level of blood concentration of cyclosporin A 
(CyA) in a patients receiving immunotherapy was observed to decrease 
following coadministration of amphotericin B (AMB).  We confirmed this 
clinical observation in experiments using Wistar rats intravenously given 
AMB (1.5 or 3.0 mg/kg) or saline (control) for 4 days, followed by CyA 
(10 mg/kg).  The blood concentration of CyA after iv or po administration 
in both AMB groups was significantly decreased compared with the 
control.  The oral bioavailability of CyA after 1.5 or 3.0 mg/kg AMB 
treatment was decreased to 67 or 46%, respectively, of that of the control 
group.  AMB treatment increased the expression levels of mdr1a and 
mdr1b mRNAs in duodenum to about 3 times the control, and expression 
of CYP3A2 mRNA in liver was increased to about twice the control.  The 
induction of their mRNAs by AMB treatment increased the level of P-gp 
and CYP3A2 protein to about twice the control.  These findings suggest 
that the oral bioavailability of CyA is reduced as a result of both increased 
efflux transport via P-glycoprotein in the duodenum and an increased first-
pass effect of CYP3A2-mediated hepatic metabolic activity, induced by 
AMB.  We suggest that careful monitoring of CyA levels is necessary in 
the event of AMB administration to patients receiving immunotherapy with 
CyA.   
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There have been many reports of drug interactions involving cyclosporin 
A (CyA), and clinically, we have encountered a patient receiving 
immunotherapy with CyA in whom the blood concentration of CyA was 
decreased upon coadministration of amphotericin B (AMB) (Fig. 1).   
It is well known that CyA is a substrate of both the efflux transporter P-
glycoprotein (P-gp) and the metabolic enzyme cytochrome P450 (CYP3A) 
[1-3].  P-gp and/or CYP3A limit the oral bioavailability of digoxin [4], 
rifampin [4], vinblastine [5], dextromethorphan [6] and CyA [7, 8].  We 
have already shown that the blood concentration of CyA is reduced by pre-
treatment with dexamethasone [9], cyclophosphamide [10] or 
levothyroxine [11] in rats, owing to induction of P-gp and CYP3A2 in liver 
and intestine.  In those reports, we demonstrated that the oral 
bioavailability of CyA is primarily controlled by the level of CYP3A in the 
upper small intestine under physiological conditions, whereas after 
treatment with inducers, P-gp in the upper intestine also plays a significant 
role as an absorption barrier to CyA. Thus, we speculated that the reason 
for the decrease of blood concentration of CyA in the patient mentioned 
above might have been induction of P-gp and CYP.  However, no report 
is currently available on drug interaction between CyA and AMB. 
Therefore, in this study, we examined the mechanism of the decrease of 
blood concentration of CyA by using rats treated with AMB.  
 
 





Fungizone® injection (amphotericin B, AMB) and Sandimmun® injection 
(cyclosporin A, CyA) were purchased from Bristol-Myers Squibb Co. Ltd. 
(Tokyo, Japan) and Novartis Pharma Co. Ltd. (Tokyo, Japan), respectively.  
Oligonucleotide primers were custom-synthesized by Amersham 
Pharmacia Biotech (UK).  Other reagents were purchased from Sigma Co. 
(MO, USA).   
 
Animal Experiments   
 
All animal experiments were performed in accordance with the guidelines 
of the Institutional Animal Care and Use Committee of the University of 
Kanazawa.   
A 150 µL aliquot of AMB (1.5 or 3.0 mg/kg/day) was intravenously 
administered to male 8-week-old Wistar rats (Japan SLC Co., Hamamatsu, 
Japan) via a tail vein daily for 4 days.  The vehicle control rats received 
were distilled water alone for 4 days.  A 100 µL aliquot of CyA (10 
mg/kg) was injected via the femoral vein at 24 h after the last treatment 
with AMB.  Alternatively, a 500 µL aliquot of CyA (10 mg/kg) was 
orally administered at 24 h after the last treatment with AMB.  Blood 
samples (200 μL each) were collected at designated time intervals from the 
jugular vein of untreated rats and AMB-treated rats under light ether 
anaesthesia.   
 
Measurement of blood concentration of CyA   
 
Blood concentration of CyA was measured with a TDx analyzer using a 
commercial kit according to the manufacturer's instructions (Dainabot Co. 
Ltd., Tokyo, Japan).  The TDx assay is a fluorescence polarization 
immunoassay (FPIA) reagent system for the measurement of CyA [12].  
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The measurement range of blood concentration was 25-1500 ng/mL.  The 
cross-reactivities with the metabolites of CyA were 19.4% for M1 and less 
than 5% for other metabolites.    
 
Determination of laboratory data   
 
Blood samples were collected from the jugular vein under light ether 
anesthesia at 24 h after the last treatment with AMB, and the plasma was 
separated by centrifugation and stored at –30°C.  The measurements of 
laboratory data were entrusted to SRL Co. Ltd. (Tokyo, Japan). 
 
Reverse Transcriptase-polymerase Chain Reaction (RT-PCR) Assay  
 
Total RNA was isolated from the liver and intestine by using an Isogen Kit 
(Wako, Osaka).  Synthesis of cDNA from the isolated total RNA was 
carried out using RNase H- reverse transcriptase (GIBCO BRL, Rockville, 
MD).  Reverse transcription (RT) reactions were carried out in 40 mM 
KCl, 50 mM Tris-HCl (pH 8.3), 6 mM MgCl2, 1 mM dithiothreitol, 1 mM 
each of dATP, dCTP, dGTP, and dTTP, 10 units of RNase inhibitor 
(Promega, Madison, WI), 100 pmol of random hexamer, total RNA and 
200 units of the Moloney murine leukemia virus reverse transcriptase 
(Gibco-BRL, Berlin, Germany) in a final volume of 50 µL at 37°C for 60 
min.  Polymerase chain reaction (PCR) was carried out in a final volume 
of 20 µL, containing 1 µL of RT reaction mixture, 50 mM KCl, 20 mM 
Tris-HCl (pH 8.3), 2.5 mM MgCl2, 0.2 mM each of dATP, dCTP, dGTP, 
and dTTP, 10 µM each of the mixed oligonucleotide primers, and 1 unit of 
Taq DNA polymerase (Gibco-BRL).  Reported primers were used for rat 
mdr1a (511 bp) [13], for rat mdr1b (451 bp) [13], for rat CYP3A2 (252 bp) 
[14], and for rat ß-actin (456 bp) [15].  Each cycle consisted of 30 sec at 
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94°C, 60 sec at 62°C, and 75 sec at 72°C for mdr1a, mdr1b, and CYP3A2, 
and 30 sec at 94°C, 60 sec at 58°C, and 75 sec at 72°C for ß-actin.  The 
PCR reaction was run for 26 cycles for liver, for 34 cycles for intestine and 
for 22 cycles for ß-actin.   
 
Preparation of Microsomes and Plasma Membrane Fraction  
 
For preparation of microsomes, the liver was homogenized in three 
volumes of 100 mM Tris-HCl buffer (100 mM KCl, 1 mM EDTA, pH 7.4).  
Microsomes were prepared as reported previously [16] and stored at -80°C 
until use.  The intestine was quickly removed and washed with buffer 
containing 2 mM HEPES, 0.9% NaCl and 0.5 mM phenylmethylsulfonyl 
fluoride (PMSF).  Mucosa was scraped off with a slide glass on ice and 
homogenized in a buffer containing 300 mM mannitol, 5 mM EDTA, 5 
mM HEPES and 1 mM PMSF (pH 7.1).  The homogenate was 
centrifuged at 10,000 g for 20 min, and the supernatant was centrifuged at 
105,000 g for 60 min at 4°C.  The pellet was added to the buffer 
containing 500 mM KCl, 1 mM EDTA, 2 mM DTT and 50 mM KPB (pH 
7.4) and again centrifuged at 105,000 g for 60 min at 4°C.  The pellet was 
added to the buffer containing 1 mM EDTA, 2 mM DTT and 50 mM KPB 
(pH 7.4), then stored at -80°C until use. 
For the preparation of plasma membrane, the liver was homogenized 
in 10 mM Tris-HCl buffer (pH 7.5) containing 2 mM CaCl2 at 4°C.  The 
homogenate was centrifuged at 3,500 g for 10 min, and the supernatant was 
then centrifuged at 15,000 g for 30 min.  The pellet was washed, 
resuspended in 50 mM Tris-HCl buffer (pH 7.2), and twice centrifuged at 
10,000 g for 5 min, then stored at -80°C until use.  The intestine was 
quickly removed and washed with ice-cold isotonic saline containing 1 
mM phenylmethylsulfonyl fluoride (PMSF).  Mucosa was scraped off 
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with a slide glass on ice and homogenized in a buffer containing 250 mM 
sucrose, 50 mM Tris-HCl (pH 7.4), and 1 mM PMSF.  The homogenate 
was centrifuged at 3,000 g for 10 min, and the supernatant was again 
centrifuged at 15,000 g for 30 min.  The pellet was resuspended in 0.5 mL 
of a buffer containing 50 mM mannitol, 50 mM Tris-HCl (pH 7.4), and 1 
mM PMSF, and stored at -80°C until use.  Protein contents were 
measured according to the method of Lowry et al. [17]. 
 
SDS-PAGE and Immunoblotting  
  
SDS-PAGE and immunoblotting with peroxidase/antiperoxidase staining 
of the plasma membrane for P-gp and of the microsomes for CYP3A were 
carried out essentially as described by Laemmli [18] and Guengerich et al. 
[19].  The amounts of sample protein of liver and intestine were 4 and 200 
μg for CYP3A or 30 and 300 µg for P-gp, respectively.  The sample 
protein was electrophoresed on 10% sodium dodecyl sulfate-
polyacrylamide gel and transferred onto PVDF membrane filters (Millipore 
Co., Billerica, MA).  After having been blocked with 5% skim milk, the 
filters were incubated overnight at 4°C with primary antibody, mouse anti-
P-gp C219 (Dako Co., Carpinteria, CA) and rabbit anti-rat CYP3A2 
antibody (Daiichi Pure Chemicals Co. Ltd., Tokyo, Japan), and for 1 h with 
secondary antibody, anti-mouse IgG HRP-linked antibody (Cell Signaling, 
Beverly, MA) and mouse anti-rabbit IgG-HRP (Santa Cruz Bio., Santa 
Cruz, CA).  Thereafter, the sample was extensively washed with 
phosphate-buffered saline.  The immunopositive band was detected by 
means of a light-emitting nonradioactive detection system (Amersham 
International plc, Little Chalfont, Buckinghamshire, UK) with Kodak X-
Omat R film (Eastman Kodak Co., Rochester, NY).   
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 Data Analysis   
 
The pharmacokinetic parameters were estimated according to model-
independent moment analysis as described by Yamaoka et al. [20].  The 
data were analyzed using Student's t test to compare the unpaired mean 
values of two sets of data.  The number of determinations is noted in each 
table and figure.  A value of P< 0.05 or 0.01 was taken to indicate a 
significant difference between sets of data.  The electrophoresis results 





The patient was a 23-year-old man (56 kg) who had received bone marrow 
transplantation for acute myelogenous leukaemia 2 months before.  He 
had been receiving immunotherapy with oral administration of Neoral® 
capsule (Novartis Pharma Co. Ltd.; CyA, 60 mg/day, 2 times a day).  The 
trough blood concentrations of CyA were well maintained at about 100 
ng/mL.  However, he developed Aspergillus pneumonia, which was 
treated with intravenous infusion with Fungizone® injection (AMB, 1-30 
mg/day, over 6 h).  Figure 1 shows the relationship between the blood 
concentration of CyA and the dose of AMB or CyA.  Main other 
combined drugs with Saxizon® injection (Kowa Pharmaceutical Co. Ltd.; 
hydrocortisone sodium succinate, 50-100 mg/day) and the preparations of 
mixed amino acid and multiple vitamins had been used after the start of the 
transplantation.   
The blood concentration of CyA in the patient gradually decreased 
to about one-third over the 12 days following the start of coadministration 
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of AMB.  Although the CyA dose was increased to 80 mg at day 17 after 
the start of AMB treatment, the blood concentration of CyA did not 
increase immediately.  Subsequently the blood concentration of CyA 
slowly recovered, reaching about 210 ng/mL with 120 mg/day of CyA after 
34 days.  
The levels of γ-glutamyltranspeptidase (γ-GTP), alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST), parameters 
of hepatic function, were 52, 45 and 65 IU/L, respectively, in the initial 
period, and subsequently remained stable within normal ranges.  The 
value of serum creatinine as a parameter of renal function was initially 0.8 
mg/dL, but increased slightly to 1.35 mg/dL at day 9 after the start of AMB 
treatment.  Therefore, the AMB administration, which was initially 30 
mg/day daily for the first 9 days, was reduced to the same dose every 
second day until day 40.  Following the decrease of AMB dosage 
frequency, the serum creatinine level rapidly decreased to 0.8 mg/dL.  






Pharmacokinetics of CyA in rats with AMB treatment   
 
Figure 2 shows the blood concentration-time courses of CyA after i.v. 
administration of Cy A (10 mg/kg) in control rats and in rats pretreated 
with AMB (1.5 or 3.0 mg/kg/day, i.v.) for 4 days.  The blood 
concentration of CyA in the low-AMB group showed a significant, time-
dependent decrease compared with the control, and that in the high-AMB 
group showed a similar decrease.   
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Figure 3 show the blood concentration-time courses of CyA after p.o. 
administration of CyA (10 mg/kg) in control rats and in rats treated with 
AMB.  After p.o. administration, the concentration of CyA reached a 
maximum within 2-4 h in all three groups.  The maximum blood 
concentrations (Cmax) of CyA in the control, low-AMB and high-AMB 
groups were 1.16, 0.37 and 0.26 μg/mL, respectively.  The blood 
concentration of CyA was significantly and dose-dependently decreased by 
the AMB treatment.   
The pharmacokinetic parameters of CyA in the three groups are listed 
in Table 1.  After the i.v. administration, the values of the area under the 
blood concentration-time curve from 0 to 24 h (AUC0-24h) in the two AMB 
groups were significantly decreased compared with the control, and the 
values of total clearance (CLtot) were significantly increased.  The 
elimination half-life (t1/2) in the high-AMB group was significantly faster 
than that in the control group.  After the p.o. administration, the AUC0-24h 
values of the low- and high-AMB groups were significantly decreased to 
about 42 and 31% of the control, respectively.  But, the t1/2 value was not 
a significant difference among all three groups.   The values of oral 
bioavailability of CyA of the low- and high-AMB group were decreased to 
about 67 and 46% of the control, respectively.   
 
Laboratory data in rats after AMB treatment 
 
Table 2 shows the laboratory data for rats treated or not treated with AMB 
(1.5 or 3.0 mg/kg).  There was no clear difference in the body weight 
among the three groups.  The laboratory data reflecting hepatic function 
were unaffected by the AMB treatment, except for the A/G ratio.  The 
values of BUN and serum creatinine were significantly increased by the 
high-AMB treatment.   
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 RT-PCR Analysis of mdr1a, mdr1b and CYP3A2 mRNAs in intestine and 
liver   
 
Figures 4 shows the effect of AMB treatment (1.5 or 3.0 mg/kg/day, i.v., 
for 4 days) on the expression of mdr1a, mdr1b and CYP3A2 mRNAs in the 
duodenum, ileum and liver at 24 h after the last treatment.  The 
expression levels of mdr1a and mdr1b mRNAs were significantly 
increased in the duodenum, but little changed in the ileum and liver by the 
AMB treatment.  On the other hand, the expression of CYP3A2 was 
significantly induced, in the liver only, by both AMB treatments.     
 
Expression of P-gp and CYP3A in intestine and liver  
 
Figure 5 shows the effect of the AMB treatment (3.0 mg/kg/day, i.v., for 4 
days) on the expression levels of P-gp and CYP3A proteins which were 
confirmed by Western blot analysis.  The protein levels of P-gp in the 
duodenum was elevated to about twice the untreated control level by AMB 
treatment, but the level in the ileum and liver were hardly changed by 
AMB.  On the other hand, the protein levels of CYP3A in the liver was 
elevated to about twice the control level by AMB treatment, while the level 











In order to understand why the blood concentration of CyA in a 
patient receiving immunotherapy decreased following coadministration of 
AMB, we examined the effect of repeated i.v. administration of AMB (1.5 
or 3.0 mg/kg) for 4 days on the disposition kinetics of CyA in rats after i.v. 
or p.o. administration (Figs. 2, 3).  We designed that AMB is 
administered with 1.5 or 3.0 mg/kg to rats because total clearance of AMB 
of rats is about 5-times higher than that of human (0.5 mg/kg) [21].  As 
we previously clarified that dexamethasone [9] and cyclophosphamide [10] 
within 4 days after the co-administration induce P-gp and CYP3A2, in this 
study the AMB co-administerd intravenously to rats for 4 days.  The 
blood concentration of CyA after i.v. administration was significantly, 
though not dose-dependently, decreased in both AMB groups compared 
with the control.  After p.o. administration, there was a significant, dose-
dependent decrease of the blood concentration of CyA in both AMB 
groups.  The oral bioavailability of CyA was clearly decreased by AMB 
treatment (Table 1). 
It is well known that renal failure is the main side effect of AMB in 
clinical practice.  There are some reports indicating that the disposition 
kinetics of CyA is influenced by renal failure in rats.  Shibata et al. [22] 
reported that CYP3A and P-gp in liver and intestine are not likely to be 
involved in lowering the oral bioavailability of CyA in gentamicin-induced 
acute renal failure, and that a change in bile function is responsible for the 
marked decrease.  Huang et al. [23] reported that the expression level of 
P-gp in rats with glycerol-induced acute renal failure was increased 2.5-
fold in the kidney, but not in the liver or brain.  Leblond et al. [24] 
reported that chronic renal failure is associated with a decrease in total liver 
CYP450 (mainly CYP2C11, CYP3A1 and CYP3A2) activity in rats, and 
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this leads to a significant decrease in drug metabolism.  In the rats, 
hepatic function was not impaired, as judged from the laboratory data, 
whereas increases in the values of serum creatinine and BUN indicated an 
appreciable impairment of renal function by the high-AMB treatment 
(Table 2).  However, the increases of serum creatinine and BUN were not 
large compared with the increases of about 3- to 5-fold and 2- to 5-fold in 
model rats with gentamicin- or glycerol-induced renal failure, respectively 
[22-24].  Therefore, we considered that the AMB-induced renal 
impairment was not great even in the high-AMB group, and may have had 
only a slight influence on the excretion of CyA, which is metabolized 
mainly by CYP3A.   
We found that in our model the expression of mdr1a and mdr1b 
mRNAs was characteristically induced about 3-fold in the duodenum 
compared with the control, but was only slightly increased in the ileum and 
liver by both AMB treatments (Fig. 4).  Also, the expression of CYP3A2 
mRNA was increased about 2-fold over the control in the liver.  These 
results are broadly consistent with our previous findings in mice treated 
with dexamethasone (DEX) [25, 26].  Unlike DEX, AMB did not induce 
a substantial increase of CYP3A2 mRNA expression in intestine, possibly 
because the dose levels of AMB were relatively low.  This would be 
consistent with the relatively minor renal impairment.  The studies with 
DEX [9-11, 26] indicated that increased mRNA levels of mdr1a, mdr1b 
and CYP3A2 mRNAs are well reflected in increased levels of P-gp and 
CYP3A2 proteins.  In this study, also the induction of their mRNAs by 
AMB treatment increased the level of P-gp and CYP3A2 proteins (Fig. 5).  
Therefore, we consider that the oral bioavailability of CyA was reduced in 
our present animal model as a result of increased efflux transport via P-
glycoprotein in the duodenum and an increased first-pass effect of hepatic 
CYP3A2 induced by AMB.  But, it was not observed that there is a great 
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difference in the t1/2 values of CyA among three groups.  Therefore, we 
thought that the induce of CYP3A2 in the liver influences slightly to the 
disposition kinetics of CyA.  Previously we suggested that, under 
physiological conditions, the oral bioavailability of CyA is mainly 
controlled by CYP3A in the upper intestine, rather than liver, but when P-
gp is induced by steroid, the intestinal absorption of CyA may be inhibited 
[26].  Therefore, we consider that the decrease of BA by AMB treatment 
is cause by the intestinal absorption decrease via induced P-gp.   
In the case of our patient, the stable trough values of blood CyA 
concentration during repeated p.o. administration of CyA were decreased 
after repeated intravenous infusion administration of AMB was started, and 
the decrease continued for 3 weeks.  During this period, the laboratory 
data indicated relatively minor impairment of hepatic and renal function by 
AMB.  Further, the patient has been received in combination with 
hydrocortisone after the start of the transplantation, however, it was not 
observed that the hydrocortisone treatment influences slightly on the 
plasma level of CyA because the low dose of hydrocortisone (50-100 
mg/day).  Therefore, we think that the clinical observations can also be 
explained mainly in terms of the induction of P-gp in intestine by the AMB 
treatment.    
We previously clarified that the induction of P-gp and CYP3A2 
continues for 2 weeks after the final DEX treatment [27].  Here, the 
patient received repeated administration of AMB for 40 days, so it was 
difficult to predict when the levels of P-gp and CYP3A2 expression would 
recover to the control level; therefore, we chose to increase the dose of 
CyA gradually.  The level of blood CyA concentration began to increase 
7 days after increasing the dose of CyA from 120 mg/day to 160 mg/day, 
and after the dose of CyA was further increased to 240 mg/day, the blood 
CyA concentration reached 210 ng/mL.  Therefore, the blood CyA 
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concentration might have recovered to about 100 ng/mL within 40 days 
after the start of AMB treatment, if the dose had been kept at 120 mg/day 
throughout.  In other words, the P-gp and CYP3A activities might return 
to the control levels within several weeks after the start of the AMB 
treatment in spite of repeating the AMB treatment, leading to 
normalization of CyA bioavailability.  Further, there are species 
differences in hepatic metabolism and susceptibility to metabolic changes, 
so that further evaluations need to be done in vitro study using human 
hepatic microsome and/or human hepatocytes.   
In conclusion, our results indicate that the oral bioavailability of CyA 
is decreased by coadministration of AMB because of an increase of 
expression of P-gp and CYP3A induced by AMB treatment. The results in 
this animal model were consistent with our clinical observations.  
Therefore, blood concentration of drugs that are substrates of P-gp and 
CYP3A, such as CyA, should be carefully monitored in patients when 
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Figure 1. Change of blood concentration-time courses of CyA in a patient 
(23-year-old man, 56 kg) receiving immunotherapy with CyA, upon 
coadministration of AMB.  He received daily oral administration of CyA, 
and then was intravenously infused over 6 h with AMB (daily for the first 
10 days, every other day for the next 15 days).   
Keys:  , CyA blood concentration;   , CyA dose; ◊ , AMB dose 
 
Figure 2.  Blood concentration-time courses of CyA after an i.v. 
administration of CyA (10 mg/kg) in untreated rats (  ) and rats treated 
with AMB at 1.5 mg/kg (△) or 3.0 mg/kg (▲) for 4 days.   
Rats were given CyA at 24 h after the last AMB treatment.  Each point 
and bar represents the mean ± SD of four rats. 
**Significant difference between the control group and both AMB groups 
at P <0.01.  
 
Figure 3.  Blood concentration-time courses of CyA after an p.o. 
administration of CyA (10 mg/kg) in untreated rats (  ) and rats treated 
with AMB at 1.5 mg/kg (△) or 3.0 mg/kg (▲) for 4 days.   
Rats were given CyA at 24 h after the last AMB treatment.  Each point 
and bar represents the mean ± SD of four rats. 
**Significant difference between the control group and both AMB groups 
at P <0.01.  
 
Figure 4.  Effect of AMB on the expression of mdr1a, mdr1b and 
CYP3A2 mRNAs in duodenum, ileum and liver. 
-20- 
The data represent the relative expression of the mRNAs obtained as 
mRNA/β-actin mRNA ratios in the low-AMB (1.5 mg/day,   ) and high-
AMB (3.0 mg/day,   ) groups by that in the control group (   ) at 24 h 
after the last AMB treatment for 4 days. 
*, **Significant difference from the control group at P <0.05 and P <0.01, 
respectively.  
 
Figure 5. Western blot analysis of P-gp (a) and CYP3A (b) proteins in the 
duodenum, ileum and liver of rats with (   ) or without (   )AMB 
treatment, at 24 h after the last AMB treatment for 4 days.  *, **Significant 





                                               Non treatment                            AMB treatment                             
Parameters                                                                   1.5 mg/kg                      3.0 mg/kg    
i.v. administration 
   AUC0-24h ( μg h/mL) a)             45.0 ± 2.7                   28.4  ± 1.2 **               30.5 ± 1.8 **     
   MRT (h) b)                               5.96  ± 0.82                  5.01 ± 0.51                  4.67 ± 0.53 *      
   CLtot (mL/min) c)                     3.70 ± 0.22                  5.87 ± 0.19 **             5.47 ± 0.31 **    
   Vdss (L) d)                                 1.32 ± 0.31                  1.76 ± 0.35                  1.53 ± 0.23   
   t1/2 (h) e)                                    5.87 ± 0.78                  6.03 ± 0.68                  4.18 ± 0.83* 
p.o. administration 
   AUC0-24h ( μg h/mL)               8.53 ± 0.78                    3.61 ± 0.41**               2.66 ± 0.23 **  
   t1/2 (h)                                      6.32 ± 0.95                    5.86 ± 0.82                   5.97 ± 0.93 
Bioavailability (%)                         19.0                                12.7                              8.7               
Table 1.  Pharmacokinetic parameters of CyA with or without AMB (1.5 or 3.0 mg/kg) in rats 
Rats were intravenously or orally administered with CyA (10 mg/kg) at 24 h after the last AMB 
treatment in untreated rats and rats treated with AMB at 1.5 or 3.0 mg/kg for 4 days.  
Pharmacokinetic parameters were estimated according to model-independent moment analysis. 
Each value represents the mean ± SD of four mice. 
a) area under blood concentration-time curve from 0 to 24 h, b) mean residence time from 0 to 24 h, 
c) blood total clearance, d) distribution volume at the steady-state, e) elimination half-life  
*, **Significant difference between the control group and both AMB groups at P < 0.05 and 0.01, 
respectively. 
Table 2.   Physical and biochemical data in rats treated with AMB  
                                           Non treatment                     AMB treatment                                                          
                                                                          1.5 mg/kg              3.0 mg/kg 
Body weight (g)                 220±7              227 ±12                 216 ±11       
AST (IU/L)                             84 ±5                 82 ±8                     88 ±14 
ALT (IU/L)                    40 ±7        35 ±2                     38 ±13 
Albumin (g/dL)                  4.07 ±0.11           3.93 ±0.15            3.67 ±0.31   
A/G ratio                           2.23±0.15    1.97 ±0.25            1.70 ±0.31*  
Total bilirubin (mg/dL)      0.14 ±0.04          0.15 ±0.08             0.14 ±0.06  
BUN (mg/dL)                       15.1 ±1.8             26.1 ±5.9*            46.8 ±9.3**   
serum creatinine (mg/dL)     0.26 ±0.03           0.28 ±0.03            0.37 ±0.05**   
Data were measured at 24 h after the last administration of AMB (1.5 or 3.0 mg/kg i.v.)  
for 4 days in rats.  Each value represents the mean ± SD of four rats.  
*, **Significant difference between the control group and both AMB groups at P < 0.05 
 and 0.01, respectively. 
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